NEW YORK—Chester H. Fox, MD, of Buffalo, N.Y., and Josef Coresh, MD, PhD, of Baltimore have been named the 2009 Kidney Disease Outcomes Quality Initiative (KDOQI) research recipients.
“The KDOQI grant initiative funds research which answers key questions identified in a particular KDOQI guideline,” said KDOQI vice chair for research Holly J. Kramer, MD. “Every KDOQI guideline begins with a systematic review of existing literature regarding a particular topic. This systematic review then identifies the ‘holes’ in the research, areas where key information regarding clinical care is missing. KDOQI research grants seek to fill in the knowledge gaps and improve patient care.”
The grant was established in 2008 by NKF’s board of directors in an effort to expand the evidence base for CKD-related clinical practice.
The request for applications (RFA) was issued in August of last year, resulting in 16ubmissions. The grants are effective July 1 and provide support of $150,000 per year, for three years.
The 2010 KDOQI RFA will be released in September.
“When the KDOQI guidelines first came out, I audited my own charts and found that I was underdiagnosing and undertreating patients with CKD in my practice,” Fox said. “I did a qualitative study interviewing other primary care physicians and found that the problem was widespread.”
Fox’s project is called “Implementing KDOQI Guidelines in Primary Care Practices,” and it will study the process and benefits of implementing the KDOQI guidelines into practice. “It takes an average of17 years from the time evidence is known to the time it is commonly used in practice,” he added. “My research goal is to try and develop systems to work with primary care physicians to shorten this cycle.”
Fox said he would eventually like to see computer decision support protocols for CKD embedded within the practice’s electronic medical record (EMR). “A long range goal would be to include longitudinal studies showing that changes made by implementing KDOQI improve patient outcomes,” he added.
Coresh’s project is called “Complications and Prognosis of CKD in U.S. Populations,” and it aims to define how estimated kidney function and proteinuria relate to a wide range of complications including hypertension and anemia.
“Overall, CKD spans a broad range of disease from relatively early stages to very severe and our goal is to define the prognosis within each stage,” Coresh said. “This will inform physicians and patients as well as guide development of future therapies to reduce risk in CKD.”